P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. Issue 1 (4th December 2019)

• Record Type: Journal Article
• Authors: Farzad, Niloofar; Barati, Nastaran; Momtazi-Borojeni, Amir Abbas; Yazdani, Mona; Arab, Atefeh; Razazan, Atefeh; Shariat, Sheida; Mansourian, Mercedeh; Abbasi, Azam; Saberi, Zahra; Badiee, Ali; Jalali, Seyed Amir; Jaafari, Mahmoud Reza
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 47:Issue 1(2019)
• Page Start: 664
• Page End: 672
• Publication Date: 2019-12-04
• Subjects: Peptide-conjugated nanoliposomes -- P435 peptide -- prophylactic vaccine -- cytotoxic T-cell response -- HER2/neu protein -- breast cancer; Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.1080/21691401.2019.1576702
• Languages: English
• ISSNs: 2169-1401

Abstract

Abstract: The present study was aimed to develop an effective nanoliposomal vaccine delivery system with P435 HER2/neu-derived peptide conjugated to Maleimide-PEG2000-DSPE. The nanoliposome formulation composed of DSPC/DSPG/Chol/DOPE and monophosphoryl lipid A was used as an adjuvant. Liposomal formulations were prepared and their physical properties were characterized. Anti-tumoral efficacy of formulations was evaluated by immunization of tumor-bearing BALB/c mice and the generated immune response was studied by using ELISpot and flow cytometry analysis. The results of the study demonstrated Lip + DOPE + P535 formulation caused the lowest tumor size and the longest survival time in TUBO mice model and could make it a promising candidate in developing effective vaccines against HER2-positive breast cancers.